Abbott Laboratories
NYSE:ABT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Abbott Laboratories
NYSE:ABT
|
US |
|
O
|
Ocean Bio-Chem Inc
F:OBC
|
US |
|
Blackline Safety Corp
TSX:BLN
|
CA |
|
Warehouses Estates Belgium SA
XBRU:WEB
|
BE |
|
Atlas Lithium Corp
NASDAQ:ATLX
|
US |
|
Dada Nexus Ltd
NASDAQ:DADA
|
CN |
|
R
|
Renewal Fuels Inc
OTC:RNWF
|
US |
|
IntegraFin Holdings plc
LSE:IHP
|
UK |
|
Spirit Technology Solutions Ltd
ASX:ST1
|
AU |
|
C
|
Cardinal Health Inc
XBER:CLH
|
US |
|
S
|
SMX (Security Matters) PLC
NASDAQ:SMX
|
IE |
Wall Street
Price Targets
ABT Price Targets Summary
Abbott Laboratories
According to Wall Street analysts, the average 1-year price target for
ABT
is 135.18 USD
with a low forecast of 114.13 USD and a high forecast of 165.9 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ABT's stock price target?
Price Target
135.18
USD
According to Wall Street analysts, the average 1-year price target for
ABT
is 135.18 USD
with a low forecast of 114.13 USD and a high forecast of 165.9 USD.
What is Abbott Laboratories's Revenue forecast?
Projected CAGR
8%
For the last 14 years the
compound annual growth rate for
Abbott Laboratories's revenue is
5%.
The projected
CAGR
for the next 3 years is
8%.
What is Abbott Laboratories's Operating Income forecast?
Projected CAGR
18%
For the last 14 years the
compound annual growth rate for
Abbott Laboratories's operating income is
13%.
The projected
CAGR
for the next 3 years is
18%.
What is Abbott Laboratories's Net Income forecast?
Projected CAGR
23%
For the last 14 years the
compound annual growth rate for
Abbott Laboratories's net income is
2%.
The projected
CAGR
for the next 3 years is
23%.
